Elaine Tuomanen, MD, CM
Surprisingly, the morbidity and mortality rates from bacterial meningitis have remained stable since the advent of antibiotics in the 1930s. A persistent mortality rate of 30% for pneumococcal meningitis (1) is not acceptable in the current chemotherapeutic era, yet the development of more highly bactericidal antibiotics has not improved disease outcome. Recently, important clues have emerged to explain this paradox. The new concept propelling changes in therapeutic regimens is that reducing inflammation is required in addition to killing bacteria in order to minimize neurologic injury during infections in the subarachnoid space. Within the next 5 years introduction of ancillary modes
Tuomanen E. Partner Drugs: A New Outlook for Bacterial Meningitis. Ann Intern Med. ;109:690–692. doi: 10.7326/0003-4819-109-9-690
Download citation file:
Published: Ann Intern Med. 1988;109(9):690-692.
CNS Infections, Infectious Disease, Neurology.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use